Navigation Links
Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
Date:12/9/2007

- MGCD0103 Continues to Demonstrate Single-Agent Activity - 38% Response Rate, 43% Disease Control Rate and 86% Tumor Reduction Rate in Heavily-Pretreated Patients with Relapsed or Refractory Hodgkin Lymphoma

in 110mg Cohort - 67% Tumor Reduction Rate in Relapsed or Refractory Non-Hodgkin Lymphoma, Including an 18% Response Rate in Evaluable Diffuse Large B- cell Patients

ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced data from two ongoing Phase 2 studies with MGCD0103, the Companies' novel, isotype-selective histone deacetylase (HDAC) inhibitor, as a single-agent in the treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Data from these studies were presented today at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH).

"These exploratory Phase 2 trials show meaningful activity of MGCD0103 in patients with differing types of lymphomas," said Patrick J. Mahaffy, president and chief executive officer of Pharmion. "This is important not only for the continuing development of MGCD0103 but also because it provides further evidence for the role of epigenetic therapies in the treatment of hematologic malignancies."

"Data from these most recent trials continue to demonstrate the single- agent potential for MGCD0103 in a patient population that currently has few effective therapeutic options," said Donald F. Corcoran, president and chief executive officer of MethylGene. "With our partners, we will continue to evaluate our current and near-term MGCD0103 clinical trials during 2008 with the goal to develop a potential registrational pathway."

Isotype Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin lymphoma (HL), Abstract #2566 (Trial 010)

To date, 33 patients
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
2. Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
3. Virginia Tech Report Has National Importance
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
6. Haemacure Reports Third Quarter 2007 Results
7. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
8. Biotech Finishes on a High in August, Burrill Report Says
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... developed at Brown University, promises to improve our understanding of ... tomography, or CT, delivers detailed 3-D images, but CT scanners ... that uses X-rays to view objects, can produce moving images ... surgeon trying to figure out the best way to repair ...
... All India Institute of Medical Sciences (AIIMS) director P. ... public relation officer filed a police complaint against him. ... relation officer of AIIMS, has filed a police complaint ... accusing Venugopal of harassment, wrongful restraint from entering office, ...
... is obviously a difficult question to answer. //There is no ... research that this is a fast growing and potentially widespread ... funded national stem cell depository would allow unfettered access for ... in the future. Unfortunately parents come to us because that ...
... want to help smokers kick ‘butts’; keep all warnings// printed ... ,The UN’s World Health Organization (WHO) identifies smoking ... ,It is responsible for the death of one in 10 ... , The researchers led by David Hammond, Ph.D., of ...
... campaign pointing out the threat of losing vision due ... young population//. This was cited by the British Journal ... Institute of the Blind, losing vision is considered more ... stroke and lung cancer associated with it. Hence the ...
... even today. But whether patients survive cancer seems to depend ... to spend// on the drugs, according to a Canadian report. ... treatment, and some Canadians will live and some will die ... Coalition of Canada report. ,The latest cancer treatments ...
Cached Medicine News:Health News:AIIMS Official Files Complaint Against Venugopal 2Health News:Statutory Warnings on Cigarette Packs- Make It Bigger and Brighter, Say Researchers 2Health News:Call for a National 'Drugs Funding Program' for Cancer Treatment in Canada 2
(Date:12/17/2014)... BUENA, N.J. , Dec. 17, 2014  IGI ... announced today the closing of its offering of $125 ... due 2019 (the "Notes").  The Notes were offered and ... 144A under the Securities Act of 1933, as amended ... at a fixed rate of 3.75% per year, payable ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, ... (CTMC), and Integrated Clinical Trial Services, LLC (ICTS), ... for clinical trials announce that they have formed ... Services (i-CTMS). i-CTMS will provide a broad range ... biotechnology and medical device companies. i-CTMS ...
(Date:12/15/2014)... LONDON , December 15, 2014 /PRNewswire/ ... Am 19. und 20. Februar ... das Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ... zu besuchen. Diese Tagung ... Gemeinschaft die Möglichkeit geben, die neue profitablen ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... ... a new market research report is available in its ... Market Perspective , http://www.reportlinker.com/p0164258/Cardiac-Biomarkers---A-Global-Market-Perspective.html , ... served as primary growth drivers for cardiac biomarkers market, ...
... , ... announces that a new market research report is available ... A Global Market Review , http://www.reportlinker.com/p0164337/Radiation-Therapy-Equipment---A-Global-Market-Review.html ... of new cancer cases diagnosed each year. Radiation therapy ...
Cached Medicine Technology:Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... Arthrotek® Precision Hand Instruments were developed ... tactile feel, while still having an instrument ... spaces without the fear of the bending ... designed and manufactured to conform to the ...
Medicine Products: